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Abstract
Background: While the role of the gut microbiome in inflammation and colorectal cancers has received much
recent attention, there are few data to support an association between the oral microbiome and head and neck
squamous cell carcinomas. Prior investigations have been limited to comparisons of microbiota obtained from
surface swabs of the oral cavity. This study aims to identify microbiomic differences in paired tumor and non-tumor
tissue samples in a large group of 121 patients with head and neck squamous cell carcinomas and correlate these
differences with clinical-pathologic features.
Methods: Total DNA was extracted from paired normal and tumor resection specimens from 169 patients; 242
samples from 121 patients were included in the final analysis. Microbiomic content of each sample was determined
using 16S rDNA amplicon sequencing. Bioinformatic analysis was performed using QIIME algorithms. F-testing on
cluster strength, Wilcoxon signed-rank testing on differential relative abundances of paired tumor-normal samples,
and Wilcoxon rank-sum testing on the association of T-stage with relative abundances were conducted in R.
Results: We observed no significant difference in measures of alpha diversity between tumor and normal tissue
(Shannon index: p = 0.13, phylogenetic diversity: p = 0.42). Similarly, although we observed statistically significantly
differences in both weighted (p = 0.01) and unweighted (p = 0.04) Unifrac distances between tissue types, the
tumor/normal grouping explained only a small proportion of the overall variation in the samples (weighted R2 = 0.
01, unweighted R2 < 0.01).
Notably, however, when comparing the relative abundances of individual taxa between matched pairs of tumor
and normal tissue, we observed that Actinomyces and its parent taxa up to the phylum level were significantly
depleted in tumor relative to normal tissue (q < 0.01), while Parvimonas was increased in tumor relative to normal
tissue (q = 0.01). These differences were more pronounced among patients with more extensive disease as
measured by higher T-stage.
Conclusions: Matched pairs analysis of individual tumor-normal pairs revealed significant differences in relative
abundance of specific taxa, namely in the genus Actinomyces. These differences were more pronounced among
patients with higher T-stage. Our observations suggest further experiments to interrogate potential novel mechanisms
relevant to carcinogenesis associated with alterations of the oral microbiome that may have consequences for the
human host.
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Background
Interactions between microbes and carcinogenesis
within the host have been studied for decades. The best
example is in the context of a single microorganism:
Helicobacter pylori and its proven link with gastric can-
cer [1]. At the other end of the spectrum, and more
recently, Fusobacterium nucleatum was described in the
gut of those with advanced colorectal cancer [2, 3]. Sub-
sequent functional studies demonstrated F. nucleatum
to be capable of both upregulating inflammatory and
oncogenic pathways in colon cancer cell lines [4] and in-
ducing adenomas in mice [5]. The bacterial microbiome,
defined as the total collection of bacteria that inhabit
any environmental niche, has been increasingly recog-
nized as an active participant in human body functions
and proposed to be an organ in its own right. At a basic
level, we have long understood that the microbiome
serves to maintain homeostasis. Dysbiosis, or disruption
of the normal flora, can result in pathogenic overgrowth
of organisms including Clostridium and Candida in the
gastrointestinal and vaginal tracts, respectively [6–8]. Simi-
larly, the oral microbiome has long been studied in the
context of dental caries: ingestion of excessive carbohy-
drates promotes overgrowth of acidogenic and acidophilic
microbes, inducing a local drop in pH, demineralization of
enamel, and subsequent breakdown of tooth [9, 10].
While investigation of the association between microbial
dysbiosis and colorectal cancer is progressing at a rapid
pace, the study of the bacterial microbiome in other areas
of the gastrointestinal tract has lagged behind. In particu-
lar, head and neck squamous cell carcinomas (HNSCC),
which account for more than half a million cancer cases
annually around the world [11, 12], has received relatively
little attention. This may be due to the fact that HNSCC is
a heterogeneous disease entity, encompassing a variety of
cancers from different disease sites, and develops from the
mucosal linings of the upper aerodigestive tract, compris-
ing: (1) the nasal cavity and paranasal sinuses; (2) the
nasopharynx; (3) the oral cavity and oropharynx; and (4)
the hypopharynx, larynx, and trachea [13]. Additionally,
major risk factors such as smoking, alcohol consumption,
and human papillomavirus infection have already been
elucidated [13, 14].
However, recent studies have identified microbiomic
shifts in the oral cavity associated with cigarette smoking,
and in the gastrointestinal tract associated with alcohol
consumption [15, 16]. Similar to the pathogenesis of
dental caries, it is feasible that the microbiome helps
transduce an environmental exposure into a carcinogenic
effect. As there are few effective systemic therapies in
HNSCC, and toxicity of local treatment is often significant
due to the vital structures involved, identification of a
microbial pathway to disease may offer new insights into
targeted therapies and primary prevention.
Prior work investigating the microbiome of head and
neck cancer, including the largest cohort that was previ-
ously reported by our group, provided descriptive evidence
of the “in”vironment of the head and neck at higher-order
taxa and suggested that microbial variation correlates with
clinical outcomes and gene methylation status [17]. Smaller
studies that have used superficial sampling of oral cavity
cancers by means of oral swabs observed differences in
taxonomic abundance between normal and tumor surfaces
primarily at the phylum level [18, 19]. However, bacteria in
the head and neck are clearly not limited to the mucosal
surface, but in fact populate deep tissue [17, 20, 21]. These
findings are supported by our prior pilot study as well as a
recent investigation composed of 29 patients with exclu-
sively laryngeal cancer that demonstrated phylum and
genus-level changes in tumor relative to normal tissue [22].
However, the significance of the findings from these studies
is unclear. Furthermore, the microbiome content of cancer-
ous mucosal tissue compared to adjacent histologically
normal tissue has not been examined outside of the setting
of laryngeal cancer.
With increasing evidence that a rich community of
bacteria exists within head and neck tissues and may
contribute to carcinogenesis, we now seek to identify
microbiomic differences between tumor and histologi-
cally normal tissue in a large cohort of patients with
HNSCC of the oral cavity, oropharynx, hypopharynx,
and larynx. In this study, we report on the largest human
tissue microbiome study in HNSCC patients, with 16S
ribosomal DNA (rDNA) amplicon sequencing of paired
normal-tumor tissue samples from 121 unrelated parti-
cipnts. With these data, we correlate whole microbiome
communities of head and neck tissue with clinical out-
come measures of HNSCC, in order to test the hypoth-
esis that microbiomes either alter or have been altered
by both the presence and extent of HNSCC.
Methods
Patient cohort and sample collection
From 2003 to 2014, consecutive HNSCC patients were
enrolled into a tissue biorepository collection. The tissue
banking protocol was designed specifically to maintain
sterility for downstream microbiome analysis. All tissues
banked were required to be collected from the oral
cavity, oropharynx, hypopharynx, or larynx. In this regis-
try, 169 individuals had available paired adjacent normal
and tumor tissue. A total of 30–50 mg each of paired
tumor and normal tissue, approximately 2 cm from the
tumor edge, were sterilely collected in the operating
room, classified via pathology review, flash frozen, and
stored at –80 °C. Relevant clinicopathologic features
were collected prospectively at the time of diagnosis.
Tumor node metastases staging was determined for each
primary tumor based on American Joint Committee on
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Cancer guidelines [23]. Missing data were filled in via
retrospective chart review; individuals without available
data were noted as such in Table 1.
DNA extraction
Total DNA was extracted with modifications from a
previously described protocol [17]. Bead homogenization
of tissues was performed with a TissueLyser II (Qiagen,
Venlo, The Netherlands). Also added was a yeast cell
wall lysis step using the Masterpure Yeast DNA Purifica-
tion kit (Epicentre, Madison, WI, USA) [24]. All beads,
tubes, and non-enzymatic reagents were treated with
ultraviolet light for at least 30 min prior to use [25]. Re-
agent controls were confirmed by 16S polymerase chain
reaction (PCR) to be absent of contaminating bacteria.
16S rRNA gene sequencing
PCR of the V1–V4 hypervariable regions of the 16S rRNA
gene was performed with previously published primers
[17]. PCR was performed under the following conditions:
95 °C for 5 min, followed by 32 cycles of 95 °C for 1 min,
55 °C for 40 s, 70 °C for 80 s, and an extension of 72 °C
for 10 min. PCR products were electrophoresed on a
1% agarose gel, purified using a Zymoclean DNA Gel
Recovery kit (Zymo, Orange, CA, USA), and cloned
into a StrataClone pSC vector (Agilent, Santa Clara,
CA, USA) [17]. From an initial 169 pairs of patient
samples, a total of 318 tissue samples from 159 distinct
patients had positive 16S rDNA PCR product recovery.
Ninety-five colonies were picked per tissue sample.
Plasmid inserts were PCR amplified using standard T3/
T7 primers, then Sanger sequenced (ABI3730xl, Life
Technologies, Carlsbad, CA, USA).
Bioinformatic analysis
Reads were filtered for quality, trimmed, and compiled
using a custom python script. Depth of coverage was set
at 60 sequences or higher based on leveling off of the
Shannon diversity index at 60 reads. Due to this cutoff, a
total of 242 tissue samples from 121 distinct patients
were included in the final analysis. Subsampled open-
reference operational taxonomic unit (OTU) picking
[26] against Greengenes (version 13.8) [27, 28] at 97%
similarity threshold using UCLUST [29], alignment with
PyNAST [30], phylogenetic tree construction using
FastTree (version 2.1.3) [31], and subsequent computa-
tion of alpha (Shannon diversity index, phylogenetic
diversity) [32, 33] and beta diversity measures (weighted
and unweighted Unifrac distances) [34, 35] was per-
formed using QIIME (version 1.9.1) [36].
Statistics
Student’s t-tests and likelihood ratio tests were used to
compare continuous and categorical demographics/






Age (years) 63 ± 11 62 ± 13 0.73
Male 74 (64) 25 (74) 0.31
Race 0.07
White 71 (91) 19 (100)
Black 7 (9) 0 (0)
Localization 0.32
Oral cavity/Oropharynx 72 (65) 26 (74)
Floor of mouth 5 2
Tongue 42 11
Tonsil 13 8
Oral cavity NOS 12 5




Low T-stage 44 (40) 15 (45)
T0 4 2
T1–T2 42 13
High T-stage (T3–T4) 66 (60) 18 (55)
N-stage 0.58
Node negative (N0) 56 (51) 15 (45)




I–II 24 (24) 4 (13)
III–IV 78 (76) 28 (88)
Previous treatment
Operation 21 (19) 4 (12) 0.37
Chemotherapy 24 (21) 3 (9) 0.09
Radiotherapy 30 (26) 8 (24) 0.78
Smoking history 0.08
Current 18 (16) 1 (3)
Past 68 (60) 24 (71)
Never 29 (25) 9 (26)
Alcohol use 0.96
Heavy 10 (9) 4 (12)
Social 57 (50) 16 (47)
History 10 (9) 3 (9)
Never 37 (32) 11 (32)
Values are presented as means ± standard deviations or
number (percent)
aData are missing for the following variables, indicated as “variable
name: # missing in included group/# missing in excluded group”:
Age: 7/5, Gender: 6/4, Localization: 11/3, Race: 43/19, T-stage 9/5, N-
stage 11/5, Overall stage: 19/6, Prior operation: 8/5, Prior chemother-
apy: 5/4, Prior radiation: 5/4, Smoking history: 6/4, Alcohol use: 7/4.
Percentages are calculated from denominator of samples with
known data
NOS not otherwise specified
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clinical factors, respectively, between patient samples in-
cluded in the final analysis and those excluded due to in-
sufficient reads. Student’s t-tests were used to compare
Shannon index and phylogenetic diversity between
tumor and non-tumor samples at a sequencing depth of
60 with ten iterations per sample. Distance matrices of
the tumor and non-tumor samples were compared using
the Adonis statistical method [37]. This method is simi-
lar to non-parametric analysis of variance (ANOVA) and
relies on F-tests based on sequential sums of squares
derived from 1000 permutations on the weighted and
unweighted UniFrac distance matrices, with the null
hypothesis that there is no difference in community
structure between groups. To compare relative abun-
dances of taxa between matched tumor-normal pairs, we
used the non-parametric two-sided Wilcoxon signed-
rank test. To compare relative abundances of taxa
between samples of different T-stages, we used the
Wilcoxon rank-sum.
All analyses were conducted in JMP Pro 12 (SAS
Institute Inc., Cary, NC, USA) or R version 3.2.2. All
statistical tests were two-sided, with a p value < 0.05
or false discovery rate (FDR) adjusted q < 0.05 consid-
ered statistically significant. All graphs were created
using the R package lattice [38]. The cladogram was
created using GraPhlAn on Galaxy [39, 40].
Results
HNSCC microbiomes are similar on a phylum-level to
those in previous studies of human oral flora
We analyzed sterilely collected, paired fresh-frozen
normal-tumor samples from 121 patients with HNSCC.
These patients were not significantly different on any
demographic or clinical factors when compared to the
38 patients excluded based on low read count (Table 1).
The taxonomic composition of our HNSCC samples is
similar to that identified in our previous pilot study of
HNSCC [17], as well as with data from previously pub-
lished studies on the human oral microbiome [41–43].
Firmicutes is the predominant phylum, followed by
Bacteroidetes and Proteobacteria, then by Fusobacteria
and Actinobacteria, in both tumor and adjacent normal
samples from HNSCC patients as well as in prior studies
(Fig. 1). Phyla falling under 0.1% relative abundance in
our dataset were not included in this analysis.
HNSCC tumor and paired-normal tissue are not significantly
different on measures of alpha or beta diversity
The average number of reads for the 242 patient sam-
ples in the final analysis was 83 ± 11 and did not differ
between tumor (84 ± 13) and normal (83 ± 7) samples
(p = 0.48). The average read length was 745 ± 117. To
determine whether overall mean diversity was different in
tumor and adjacent normal tissue of HNSCC patients, we
compared two measures of alpha diversity: Shannon index
(H) which measures the evenness and richness of a popu-
lation; and phylogenetic diversity (PD) which takes the
phylogenetic relationship between taxa into account. We
found no significant difference in measures of alpha diver-
sity between tumor (H =mean 3.72 ± standard error 0.78,
PD = 6.42 ± 1.88) and normal (H = 3.87 ± 0.74, PD = 6.62
± 1.96) tissue (H: p = 0.13, PD: p = 0.42).
To test whether overall bacterial taxa composition
was different between tumor and normal tissue, we
used principal coordinates analysis (PCoA) on weighted
and unweighted Unifrac distances. We found that,
although statistically significantly different on both
weighted (p = 0.012) and unweighted (p = 0.042) mea-
sures, the tumor/normal grouping explained only a
small proportion of the overall variation in the samples
(Fig. 2a, Additional file 1: Figure S1A, B). This differ-
ence was also similarly significant (weighted p = 0.001,
unweighted p = 0.001) but non-explanatory when compar-
ing PCoAs of samples by whether they were from the oral
cavity/oropharynx or the hypopharynx/larynx (Fig. 2b).
Relative abundance of specific taxa differs between
tumor and paired normal tissue
Next, we compared the relative abundances of 372 individ-
ual taxa between matched pairs of tumor and adjacent nor-
mal tissue, finding differences in ten genera, 12 families,
eight orders, five classes, and three phyla by Wilcoxon
signed-rank testing (Additional file 2: Figure S2). Only 2/10
genera were significant after adjusting for FDR: Actinomyces
and Parvimonas. The genus Actinomyces, along with its
parent family Actinomycetaceae, order Actinomycetales,
class Actinobacteria, and phylum Actinobacteria, was
depleted in tumor compared to matched normal tissue. In
contrast, the genus Parvimonas, along with its parent fam-
ily Tissierellaceae, was increased in tumor compared to
normal tissue (Fig. 3).
After identifying taxa that were significantly different
between tumor and paired normal tissues, we performed
a stratified analysis to investigate the relationship be-
tween tumor stage and the relative abundances of these
taxa. We observed that samples from low-stage (T0–2)
patients had significantly increased relative abundance of
the genus Actinomyces compared to samples from
high-stage (T3–4) patients (median 3.3% versus 1.2%,
p = 0.005). The parent taxa of the genus Actinomyces
were also significantly relatively increased in low-stage
patients compared to higher stages, up to the phylum
level. In contrast, the genus Parvimonas was significantly
relatively decreased in samples from low-stage patients
compared to high-stage patients (median 0.0% versus
1.1%, p = 0.023). The relationship between these taxa and
T-stage remained consistent when stratifying by tumor
versus paired-normal tissue (Fig. 4a). This difference was
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statistically significant in the normal group (phylum Actino-
bacteria p = 0.002, genus Actinomyces p = 0.023, genus Par-
vimonas p = 0.033), but only approached significance in the
tumor group (phylum Actinobacteria p = 0.067, genus Acti-
nomyces p = 0.052, genus Parvimonas p = 0.247).
As T-stage was significantly associated with tissue loca-
tion (oral cavity/oropharynx versus hypopharynx/larynx),
we proceeded to stratify samples based on tissue location
(Fig. 4b). We observed that relative abundances of the
phylum Actinobacteria, genus Actinomyces, and genus
Parvimonas were consistently lower at hypopharyngeal/la-
ryngeal locations relative to the oral cavity/oropharynx.
However, when analyzing oral cavity/oropharynx samples
alone, Actinobacteria and Actinomyces approached signifi-
cance in low-stage patients relative to high-stage patients
(p = 0.100, p = 0.192) and Parvimonas remained signifi-
cantly relatively decreased among low-stage patients com-
pared to high-stage patients (p = 0.006). When analyzing
hypopharyngeal/laryngeal samples alone, Actinobacteria
remained significantly relatively increased in low-stage
patients (p = 0.031), while Actinomyces and Parvimonas
were not significantly different between low-stage and
high-stage groups (p = 0.645, p = 0.790).
Discussion
In this study, we sought to describe the oral microbiome
of individuals with HNSCC and to compare the local
microbiome of their tumors with neighboring normal
tissue. We hypothesized that tumor tissue would have a
microbiome unique from that of adjacent normal tissue
and be more pronounced in higher stage disease. The
simple comparison of tumor versus adjacent normal tis-
sue did not reveal major shifts in overall diversity (Shan-
non index or phylogenetic diversity) or in microbiomic
content. However, matched pairs analysis of individual
tumor-normal pairs revealed significant differences in
relative abundance of specific taxa, namely the genera Ac-
tinomyces and Parvimonas. These differences were more
pronounced in patients with a higher T-stage.
The phylum-level oral microbiome of individuals in our
study was similar to those reported previously. Dewhirst
et al. reported on the Human Oral Microbiome Database,
which consisted of 633 Sanger-sequenced oral 16 s rRNA
gene libraries from various head and neck sites of patients
of various states of health and disease [41]. Ahn et al. ana-
lyzed oral washes from 20 individuals (ten with malignant
or premalignant oral lesions, ten healthy controls) using
both 16 s rRNA pyrosequencing and a custom DNA
microarray [42]. Segata et al. found in their study of over
200 healthy adults that the adult digestive tract micro-
biome differed according to location of sampling; group 1
(G1) sites (buccal mucosa, keratinized gingiva, and hard
palate) had increased relative abundance of Firmicutes
and decreased relative abundance of other phyla as com-
pared to group 2 (G2) sites (saliva, tongue, tonsils, and
throat) [43]. The phyla-level composition of our study
population was most similar to Segata et al.’s G2 series,
despite the fact that they used next-generation sequencing
(NGS) instead of Sanger sequencing, used swabs instead
of surgically excised tissue, and had healthy controls in-
stead of patients with HNSCC. This was not surprising
given that the majority of our patient tissues were from
Fig. 1 Relative abundances of major phyla in the human oral microbiome. Bar plot of relative abundances of major phyla in the oral microbiome
observed in this study and three previously published series. There were similar relative abundances of the most common phyla among tumor
(orange) and adjacent normal (blue) tissue from this study. Additionally, these abundances were similar to previously published series describing
the oral microbiome
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tongue and tonsil locations (Table 1), as in Segata et al.’s
G2 series [43].
We did not observe any differences in overall diversity
of tumor and adjacent normal tissue samples from
HNSCC patients. On analysis of alpha diversity mea-
sures, we found that the Shannon diversity index of our
samples was similar to previously reported measures [44,
45]. Median phylogenetic diversity of our samples was
lower than the median described by Takeshita et al. in
their study of over 2000 healthy Japanese individuals
[46]. This suggests that our study, which uses Sanger se-
quencing and thus has fewer reads, may under-predict
the true phylogenetic diversity of patient samples. How-
ever, this difference may also be due to differences in
Fig. 2 PCoA plots of weighted and unweighted UniFrac distances of tumor and normal samples. Overall oral microbiomic diversity of patient
samples as represented by PCoA of weighted and unweighted UniFrac distances. In panel (a), each point represents a single tumor (orange
square) or adjacent normal (blue circle) sample, with plus sign and ellipses (orange solid line = tumor, blue dashed line = normal) representing the
fitted mean and 68% confidence interval of each group, respectively. Adonis testing revealed statistically significant clustering based on the
tumor/normal grouping (weighted p = 0.012, unweighted p = 0.042), but this clustering only explained a small proportion of the overall variation
among samples (weighted R2 = 0.010, unweighted R2 = 0.006). In panel (b), each point represents a single oral cavity/oropharyngeal (magenta) or
hypopharyngeal/laryngeal (green) sample, with plus sign and ellipses (magenta solid line = oral cavity/oropharynx, green dashed line = hypopharynx/
larynx) representing the fitted mean and 68% confidence interval of each group respectively. The different shapes provided by the legend
delineate smaller sub-categories of each location. Adonis testing revealed statistically significant clustering of oral cavity/oropharyngeal samples
relative to hypopharyngeal/laryngeal samples (weighted p = 0.001, unweighted p = 0.001), but this clustering only explained a small proportion of
the overall variation among samples (weighted R2 = 0.018, unweighted R2 = 0.014)
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patient disease status, ethnicity, diet, and/or sample type
(saliva versus tissue).
Although our samples did cluster into statistically sig-
nificant normal and tumor groups based on weighted
and unweighted UniFrac distances, this grouping only
explained a small proportion of the overall variation seen
in our samples (Fig. 2). This is unsurprising considering
the relative proximity (2 cm) of these two categories of
tissue. In fact, the relative histological similarity of adja-
cent “normal” tissue to neighboring tumor tissue was
first described in oral epithelia, and given the name
“field cancerization” [47]. Coined to designate large areas
of premalignant tissue with altered histology adjacent to
malignant tumor tissue, field cancerization may also
apply to the resident microbiome. These data imply that
more similarities than differences exist between the
overall oral microbiomes of tumor and adjacent normal
tissues from the same patient, consistent with what has
been described previously in a smaller series [18].
Despite similarities on the community level, we ob-
served differences between matched pairs of tumor and
normal samples on the individual taxon level. Relative
abundances of the genus Actinomyces, along with its
parent taxa up to the phylum level, were significantly de-
creased in tumor as compared with normal samples
(Fig. 4). Schmidt et al. also described a decrease in the
relative abundance of 11 OTUs from the phylum Acti-
nobacteria in swabs of tumor sites as compared to
contralateral normal mucosa in 13 individuals with
HNSCC [18]. Similarly, Gong et al. observed decreased
levels of Actinobacteria in 27 patients with laryngeal car-
cinoma compared to 28 participants with vocal cord
polyps [19].
Members of the genus Actinomyces are human com-
mensals in the oropharynx, gastrointestinal, and female
genital tracts, but can rarely cause subacute to chronic
infections in the setting of mucosal disruption [48].
While neither this investigation nor the abovementioned
studies can establish the nature or timeline of the rela-
tionship between depletion of Actinomyces and malig-
nancy, it is possible that Actinomyces spp. exert a
protective effect through the secretion protease-
inhibitors that inhibit tumorigenesis [49]. Alternatively,
Actinomyces spp. could be out-competed by faster-
growing oral commensals at the relatively acidic, hyp-
oxic, and glucose-starved tumor microenvironment [50].
This hypothesis would be most consistent with our ob-
servation that relative abundances of Actinomyces and
Actinobacteria were not only decreased in tumor com-
pared to adjacent normal tissue, but more so in higher
T-stage samples (Fig. 4, top and middle). The effect of
T-stage was more pronounced in adjacent normal tissue
than in tumor, suggesting that Actinomyces depletion
may precede tumor invasion. Importantly, node positiv-
ity was not associated with Actinomyces relative abun-
dance, indicating that it may not have a role in the
tumor’s metastatic potential.
Although a statistically significant difference in the
relative abundance of genus Parvimonas was observed
between tumor and adjacent normal tissue, the absolute
difference was small and may not be clinically relevant.
In addition, although the increase in genus Fusobacter-
ium and its parent taxa up to the phylum level in tumor
samples was not statistically significant after correction
for multiple comparisons, this finding is consistent with
previous reports [18] and may be important in the con-
text of what is known about Fusobacterium and colorec-
tal cancer [2, 3, 5].
This investigation represents the largest study of the
microbiome of patients with HSNCC to date, with 121
matched tumor and adjacent normal samples. Moreover,
a non-parametric matched pairs analysis was conducted,
in contrast to prior studies, which allowed us to control
for demographics, clinical characteristics, lifestyle factors,
Fig. 3 Significant taxa by Wilcoxon signed-rank in paired tumor and normal tissue. Box plots representing relative abundances of taxa observed to
be significantly different between tumor (orange) and adjacent normal (blue) samples by paired Wilcoxon signed-rank testing after correction for FDR.
Dark vertical lines represent the median, with the box representing the first (Q1) and third (Q3) quartiles, and the outer fences 1.5 × interquartile range.
Outliers are not plotted. Values are reported as median (Q1–Q3), with q values representing significance of Wilcoxon signed-rank comparing tumor
and normal relative abundances for each taxon after FDR correction. Taxa names are colored based on the group in which they are overrepresented
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and inherent inter-individual microbiomic variability
when comparing tumor and normal samples. In contrast
to prior investigations that used swabs or oral rinses, we
used surgically excised, histologically verified, tumor and
adjacent normal tissue. This offers the capacity to directly
sample the tumor microenvironment and compare it to
the microenvironment of adjacent normal tissue.
At the time of protocol initiation, NGS was less widely
available relative to Sanger sequencing. While this is a
limitation of our investigation due to the relatively low
read counts in our study, there is evidence to suggest
that useful comparisons can be made at this sequencing
depth [51]. Prior studies have demonstrated that low
numbers of reads can accurately characterize communi-
ties at the phylum level and be used to uncover large-
scale differences between communities through analysis
of beta-diversity metrics [34, 52, 53]. Other studies have
demonstrated that while Sanger sequencing (at a depth
of 50 reads per sample) will miss rare species, it can cap-
ture most of the microbial diversity and accurately
characterize abundances of predominant taxa [54, 55].
We acknowledge that the power to detect statistically
significant differences in relative abundances is limited
by the low read counts offered by Sanger sequencing. As
such, the likelihood of false negatives in this study is
quite high. However, despite low read counts, significant
Fig. 4 Relative abundances of differentially represented taxa stratified by T-stage. Box plots representing relative abundances of phylum Actinobacteria
(top), genus Actinomyces (middle), and genus Parvimonas (bottom) stratified by T-stage. Dark horizontal lines represent the median, with the box representing
the first (Q1) and third (Q3) quartiles, and the outer fences 1.5 × interquartile range. Outliers are not plotted. a Samples stratified by type
(normal = blue, tumor = orange), with darker colors representing higher T-stage. In both normal and tumor samples, the relative abundances
of Actinobacteria and Actinomyces decrease, while Parvimonas increases, with increasing T-stage. b Samples stratified by location (oral cavity/oropharynx =
magenta, hypopharynx/larynx = green), with darker colors representing higher T-stage. In the oral cavity/oropharynx, the relative abundances of
Actinobacteria and Actinomyces decrease, while Parvimonas increases, with increasing T-stage. In hypopharyngeal/laryngeal samples, only Actinobacteria is
decreased with increasing T-stage
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differences were observed, some consistent up to the
phylum level, reflecting the large effect size of these
differences.
Conclusions
We conclude that the microbiomes of HNSCC tumor mi-
croenvironments are largely similar in overall diversity
and bacterial composition to that of histologically normal
adjacent tissue. However, we detected decreases in the
genus Actinomyces and its parent taxa up to the phylum
level and found that this decrease was more pronounced
in higher T-stage samples. Further investigation is needed
to validate these findings in a large series using NGS
methods and to determine the biological relevance of this
observed difference.
Additional files
Additional file 1: Figure S1. Overall oral microbiomic diversity of patient
samples as represented by PCoA of (A) weighted and (B) unweighted
UniFrac distances. Each point represents a single tumor (orange) or normal
(blue) sample, with connecting lines delineating a tumor/normal pair from
the same patient. (TIFF 1177 kb)
Additional file 2: Figure S2. Cladogram depicting phylogenetic
relationship of taxa identified as significantly different (p< 0.05) by Wilcoxon
signed-rank testing in tumor relative to adjacent histologically normal tissue
prior to correction for FDR. Each concentric ring of nodes represents a
taxonomic rank, starting with kingdom at the very center. Moving outwards,
the rings represent phylum, class, order, family, and genus. Nodes
highlighted in orange are increased in tumor relative to normal samples.
Nodes highlighted in blue are increased in normal relative to tumor samples.
(TIFF 2213 kb)
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